SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma, a clinical-stage biopharmaceutical company focused on developing cell-permeable macrocycle therapeutics, today announced a late-breaking ...
Planned interim analysis from DENALI Part 2a showed a clearly differentiated response rate at 400mg QD 5:2 over 300mg QD 5:2 and comparable ...
“CID-078 exemplifies Circle Pharma’s commitment to advancing new treatments for patients with cancer,” said Michael C. Cox, PharmD, MHSc, BCOP, SVP, and head of early development of Circle Pharma.
The review emphasizes how breakthroughs in understanding the molecular mechanisms of cell cycle regulation have paved the way for the development of targeted anti-cancer agents. Notably, inhibitors of ...
[button url="http://chem.colorado.edu/" color="blue"]Department of Chemistry and Biochemistry[/button] [button url="www.colorado.edu" color="blue"]University of ...
Circle Pharma, a clinical-stage biopharmaceutical company dedicated to discovering and developing a new generation of macrocycle therapies, today announced a poster for preclinical data on CID-078, a ...
Within molecular biology, few regulatory proteins have attracted as much sustained attention as P21, a cyclin-dependent ...
A 'pocket' on the protein cyclin B is responsible for ensuring that the steps of cell division take place in the correct order. Cell division is key for life. Every organism -- from the smallest yeast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results